



Elenco Poster

ID N. pgm Title

Clinical Hepatitis

39	P 1	Treatment with ledipasvir/sofosbuvir for 8 weeks in naïve patients with chronic hepatitis C and genotype 1: a preliminary analysis <i>S. Mornese Pinna, L. Boglione, J. Cusato, A. De Nicolò, G. Cariti, A. D'avolio, G. Di Perri</i>
86	P 2	Response-guided treatment in the era of DAAs: is it actually a farewell? <i>G. Bruno, A. Procopio, C. Fabrizio, E. Milano, L. Monno, M. Milella, A. Saracino, G. Angarano</i>
185	P 3	Evolution of renal function abnormalities in a cohort of HCV and HCV/HIV co-infected patients treated with DAA <i>L. Montanari¹, L.a. Nicolini¹, F. Bovis², L. Taramasso¹, C. Saffioti¹, P. Tatarelli¹, E. Balletto¹, F. De Puente¹, C. Viscoli¹, A. Di Biagio¹</i>
380	P 4	High efficacy and tolerability of DAA therapy for HCV in HIV-infected patients from the real practice: the complete experience of Tuscany <i>B. Valoriani¹, E. Salomoni², M. Pozzi², S. Sani³, R. Cinelli³, B. Rossetti¹, A. Gonnelli⁴, R. Iapoce⁵, S. Fabiani⁵, D. Tacconi⁶, L. Bernini⁶, P. Blanc⁷, P. Pierotti⁷, C. Nencioni⁸, A. Nerli⁹, S. Luchi¹⁰, M. De Gennaro¹⁰, A. De Luca¹, D. Bartolozzi² On Behalf Of Simit Toscana And Epatologi Toscani</i>
338	P 5	Second Generation of Direct Antiviral Agents: an analysis of the European Pharmacovigilance Database <i>M. De Fina</i>
343	P 6	Direct antiviral agents: an analysis of the European pharmacovigilance database <i>M. De Fina</i>
13	P 7	Influence of HBV genotypes on the clinical presentation of HBV chronic infection: a study on immigrant populations living in Southern Italy <i>E. Sagnelli¹, L. Alessio², C. Sagnelli^{1,3}, L. Gualdieri⁴, M. Pisaturo⁵, C. Minichini¹, G. Di Caprio^{1,2}, M. Starace¹, L. Onorato^{1,2}, M. Macera¹, G. Scotto⁶, N. Coppola¹</i>
61	P 8	Correlation between the hepatic expression of human microRNA hsa-miR-125a-5p and the progression of fibrosis in patients with overt and occult HBV infection <i>L. Onorato¹, G. De Stefano², C. Minichini¹, V. Messina⁴, M. Starace¹, M. Panella³, P. Filippini⁴, N. Mosca³, L. Alessio⁴, N. Farella², N. Potenza³, E. Sagnelli¹, N. Coppola¹, A. Russo³</i>
92	P 9	Assessment of Non Alcoholic Fatty Liver Disease (NAFLD) in a cohort of HIV monoinfected patients <i>P. Columpsi¹, V. Zuccaro¹, L. Maiocchi², G. Ferraioli², L. Sacchi³, P. Sacchi¹, C. Filice², R. Bruno^{1,2}</i>
262	P 10	Efficacy and tolerability of treatment with the new direct acting antivirals (DAAs) in thalassemic patients with chronic Hepatitis C <i>S. Onali¹, I. Maida², C. Balestrieri³, F. Arcadu⁴, E. Urru¹, F. Pes¹, D. Porcu¹, G. Serra³, G. Flore², E. Dore², C. Satta⁴, P.p. Bitti⁵, M.g. Sanna⁵, L. Serusi⁵, M. Conti², M. Casale¹, F. Figorilli¹, M.c. Pasetto¹, L. Chessa^{1,2}</i>
107	P 11	DAA-based regimens in HBsAg /anti-HCV positive patients: the need to control HBV replication to avoid HBV reactivation <i>M. Macera¹, M. Stanzione¹, V. Messina², G. D'adamo³, V. Sangiovanni⁴, L. Miogliesi⁵, L. Fontanella⁶, S. De Pascalis¹, G. Stornaiuolo¹, A. Galeota Lanza⁷, T. Ascione⁸, G.b. Gaeta¹, I. Gentile⁹, G. Piai⁵, N. Coppola¹</i>
198	P 12	Liver steatosis in HIV-infected patients: cross-sectional analysis of prevalence, risk factors and management <i>R. Rossotti, M. Merli, C. Baiguera, L.j. Garcia-fraile Fraile, M. Puoti</i>
5	P 13	Changes in liver stiffness assessment in chronic hepatitis C patients treated with direct-acting antivirals: monocentric experience between 2015 and 2016 <i>F. Barbaro, S. Cavinato, E.m. Erne, A. Cattelan</i>
183	P 14	Drug Addicts Adherence to new DAAs in real-life: is HCV cure possible in this key population? <i>E. Teti¹, L. Foroghi¹, V. Cento², C. Stingone¹, M. Compagno¹, G. Malerba¹, A. Cavasio¹, E. Rossi³, D. Masci³, P. Sammarco³, R. Sista³, S. Capasso³, B. Coladarce³, G. Rodoquino³, M. Patti³, F. Patrino³, M. Pellegrino⁴, C. Sarrecchia¹, C.f. Perno², L. Sarmati¹, M. Barra³, M. Andreoni¹</i>
272	P 15	Hepatocellular carcinoma risk in HCV patients undergoing Direct-Acting Antivirals in field-practice <i>M. Schiavini¹, C. Magni¹, S. Landonio¹, F. Niero¹, M. Passerini¹, M. Crespi², R. Giorgi¹, A. Mainini¹, R. Bianco³, L.pennacchi², S. Passerini¹, G. Gubertini¹, E. Angeli¹, G. Rizzardini¹</i>
186	P 16	Impact of concomitant medication on efficacy and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin: analysis of phase III trials <i>M. Puoti¹, J. Petrovic², F. Marra³, D. Back³, T. Welzel⁴, S. Christensen⁵, M. Buti⁶, F. Zoulim⁷, G. Dore⁸</i>
332	P 17	Stiffness and fibrosis scores improvement in HIV/HCV coinfecting patients after DAA <i>G. Fabbri, M. Zaccarelli, I. Mastroiosa, L. Timelli, A. Vergori, S. Cicalini, R. Bellagamba, M.m. Plazzi, A. Antinori, A. Ammassari</i>
32	P 18	Pros and cons of an 18-month lamivudine prophylaxis of HBV reactivation in anti-HBc-positive/HBsAg-negative patients with hematological malignancies <i>N. Capoluongo¹, A. Marrone², C. D'amore², M. Pisaturo¹, M. Esposito³, S. Guastafierro⁴, I. Siniscalchi², M. Macera¹, A. Boemio², L. Onorato¹, L. Rinaldi², C. Minichini¹, L.e. Adinolfi², E. Sagnelli¹, L. Mastrullo³, N. Coppola¹</i>



Elenco Poster

ID	N. pgm	Title
165	P 19	Mitochondrial toxicity and body shape changes during first generation Nucleos(t)ide Analogues long term administration in HBV-infected patients <i>V. Fiore¹, G. Madeddu¹, M. Melis¹, F. Mannu⁵, A.a. Muredda¹, G. Garrucciu², F. Bandiera³, S. Zaru⁴, P. Bagella¹, S. Ortu¹, S. Babudieri¹</i>
255	P 20	Evaluation of mild cognitive dysfunction by Montreal Cognitive Assessment test in co-infected HIV-HCV patients treated with the new direct acting antivirals (DAAs) <i>F. Pes¹, S. Onali¹, C. Balestrieri², F. Figorilli¹, G. Serra², C. Pasetto¹, L. Chessa^{1,2}</i>
12	P 21	Clinical findings of HCV chronic infection in undocumented immigrants and low-income refugees in three areas of southern Italy <i>E. Sagnelli¹, L. Alessio², C. Sagnelli^{1,2,4}, L. Gualdieri⁵, M. Pisaturo^{4,2,3}, C. Minichini¹, G. Di Caprio², M. Starace¹, Lorenzo Onorato^{1,2}, G. Scotto⁶, M. Macera^{1,2}, N. Coppola¹</i>
100	P 22	Age, genotype 3 and liver stiffness > 18 KPa are related with sustained virological response (SVR12) in cirrhotic patients with hepatitis C treated with direct acting antivirals (DAAs) <i>P. Nasta, S. Odolini, S. Casari, A. Spinetti, S. Zaltron, L. Urbinati, P. Lanza, C. Quirico, A. Bonito, E. Festa, E. Pollastri, E. Chiari, F. Castelli</i>
149	P 23	Direct-acting antivirals efficacy in hepatitis C-infected and HIV/HCV co-infected patients: a real life experience <i>P. Lanza, S. Odolini, S. Casari, E. Bigoloni, A. Spinetti, S. Zaltron, P. Nasta, L. Urbinati, E. Festa, E. Pollastri, A. Bonito, F. Castelli</i>
311	P 24	Clinical and virologic outcome in a cohort of HCV+ women undergoing DAA <i>R. Marocco, I. Pozzetto, T. Tieghi, B. Kertusha, C. Del Borgo, V.s. Mercurio, M. Lichtner, C.m. Mastroianni</i>
364	P 25	Impact of treatment length (12 vs 24 weeks) on efficacy of DCV/SOF/RBV treatment in HCV-infected patients with genotype 3 and advanced liver fibrosis or compensated cirrhosis <i>L. Campana¹, A.l. Tortora², E. Visconti¹, E. Tamburrini¹, M. Pompili², A. Cingolani¹, M. Siciliano²</i>
17	P 26	Lymphoproliferative disease with mixed cryoglobulinemia and hyperviscosity syndrome in an HIV-infected patient: HCV is the only culprit <i>P. Zanotti¹, I. Izzo¹, S. Casari¹, C. Cattaneo², S. Zaltron¹, A. Spinetti¹, S. Odolini¹, C. Chirico¹, C. Grecchi¹, E. Festa¹, F. Castelli¹</i>
228	P 27	Is Rapid Virological Response at Week 4 a good Predictor of Treatment Outcome (SVR) in Patients with Chronic Hepatitis C in Direct acting antivirals (DAAs) era? <i>A. Bonito, S. Odolini, S. Casari, E. Bigoloni, A. Spinetti, S. Zaltron, P. Nasta, L. Urbinati, P. Lanza, E. Pollastri, C. Chirico, E. Festa, F. Castelli</i>
275	P 28	Spontaneous HCV clearance after trauma and splenectomy: a case-report <i>S. Dal Zoppo, S. Lorenzotti, C. Fornabaio, F. Zacchi, A. Zoncada, N. Brianese, A. Pan</i>
299	P 29	IFN-free treatment in genotype 4 HCV patients <i>C. Taibi¹, E. Giombini², M. Selleri², B. Bartolini², C. Minosse², S. Cerilli¹, L. Loiacono¹, M.r. Capobianchi², G. D'offizi¹, A.r. Garbuglia²</i>
350	P 30	Safety of Direct Acting Antivirals for treatment of chronic HCV: A Case series of adverse drug reactions in course of treatment with DAAs <i>T. Kamal Eldin, F. De Zottis, B. Pinchera, A. Spera, A.e. Maraolo, R. Scotto, E. Borgogno, E. Zappulo, M.g. Nerilli, G. Tosone, F. Minervini, G. Bonadies, I. Gentile, G. Borgia</i>
392	P 31	Sixty weeks of undetectability HCV RNA after two weeks of combination therapy with ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in a compensated cirrhosis mono-infected patient <i>C. Imburgia¹, C. Iaria¹, E.r. Dalle Nogare¹, T. Prestileo¹, A. Sanfilippo¹, F. Di Lorenzo¹, A. Ficalora¹, C. Buscemi¹, S. Marra¹, S. Corrao^{1,2}</i>
412	P 32	Assessment of cytokines profile in HCV-positive patients receiving DAAs <i>A. Occhionero¹, L. Caiazzo¹, C. Catena¹, M. Reale², F. Vignale¹, C. Ucciferri¹, K. Falasca¹, J. Vecchiet¹</i>
159	P 33	Acute HBV reactivation (rHBV) following successfull DDA treatment of HCV in a cirrhotic HIV infected patient <i>E. Barchi¹, A. Zerbini², N. Solomita¹, M. Massari¹</i>
245	P 34	Evaluation of estimated glomerular filtration rate in hepatitis C virus positive patients treated with interferon free regimens with directly acting antivirals <i>A. Strazzulla¹, G. Coppolino², G.s. Barreca³, I. Gentile⁴, L. Rivoli⁵, M.c. Postorino¹, M. Mazzitelli¹, G. Greco¹, C. Costa¹, V. Pisani¹, N. Marascio³, A. Focà³, G. Fuiano⁵, E. Gulletta⁴, C. Torti¹</i>
246	P 35	Evolution of estimated glomerular filtration rate and plasmatic neutrophil gelatinase-associated lipocalin in hepatitis C virus positive patients treated with directly acting antivirals <i>A. Strazzulla¹, G. Coppolino², G.s. Barreca³, I. Gentile⁴, L. Rivoli⁵, M.c. Postorino¹, M. Mazzitelli¹, G. Greco¹, C. Costa¹, V. Pisani¹, M.a. Simeoni⁵, D. Foti⁴, N. Marascio³, A. Focà³, G. Fuiano⁵, E. Gulletta⁴, C. Torti¹</i>
279	P 36	Regression of liver fibrosis and stability of steatosis in HIV/HCV co-infected patients treated with DAAs <i>F. Patti, A. Barco, L. Marinaro, C. Montrucchio, C. Alcantarini, C. Costa, S. Scabini, M. Milesi, M. Ferrara, M. Tettoni, A. D'avolio, G. Di Perri, S. Bonora</i>



Elenco Poster

ID	N. pgm	Title
155	P 37	Direct-Acting Antivirals (DAAs) for the treatment of HCV infection in HIV/HCV-coinfected patients: a real life experience <i>C. Valeriani^{1,4}, A. Costantini^{2,4}, A. Giacometti^{1,4}, O. Cirioni^{1,4}, B. Canovari³, M. Balducci³, S. Castelletti^{1,4}, Z. Pasquini⁴, M. Bora^{1,3,4}, F. Barchiesi⁴</i>
Clinical HIV		
339	P 38	Changes in lipid profile and MDRD after simplification to DRV/c mono and dual-therapy based regimens: data from a large Italian cohort <i>A. Vergori¹, A. Ammassari¹, F. Disora², A. Giannetti¹, A. Latini³, D. Francisci⁴, R. Bellagamba¹, I. Mezzaroma⁵, S. Cicalini¹, G. D'ettore⁵, R. Maddaluno¹, R. Monarca⁶, M. Lichtner⁷, E. Schiaroli⁸, S. Di Giambenedetto⁹, G. Maffongelli¹⁰, A. Antinori¹, M. Zaccarelli¹</i>
60	P 39	Trends and causes of hospitalization during 1998-2016 in HIV-infected persons entered specialized care in an Italian hospital <i>A. Borghetti¹, F. Lombardi¹, I. Fanti¹, L. Camoni², S. Bellino², A. Ciccullo¹, G. Baldin¹, R. Gagliardini¹, A. De Luca³, R. Cauda¹, P. Pezzotti², S. Di Giambenedetto¹</i>
88	P 40	Evolution of inflammation, monocyte activation and coagulation markers in the ATLAS-M randomized trial <i>S. Belmonti¹, F. Lombardi¹, S. Lamonica¹, A. Ciccullo¹, G. Baldin¹, R. Gagliardini¹, A. Borghetti¹, M. Fabbiani², R. Cauda¹, A. De Luca^{3,4}, S. Di Giambenedetto¹</i>
160	P 41	Compassionate use of tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: an Italian experience <i>G. Maffongelli¹, C. Cerva¹, C. Stingone¹, M.m. Plazzi², G. Fabbri², A. Vergori², P. Vitiello³, T. Quirino³, R. Rossotti⁴, E. Danieli⁴, P. Tau⁴, M. Puoti⁴, L. Gazzola⁵, A. D'armino⁵, P. Lanza⁶, F. Castelli⁶, M. Trizzino⁷, A. Cascio⁷, P. Costenaro⁸, V. Manfrin⁸, R. Ferretto⁸, M. Colafigli⁹, A. Latini⁹, C. Cristaudo⁹, R. Valentinotti¹⁰, R. Luzzati¹⁰, S. Salpietro¹¹, E. Carini¹¹, A. Castagna¹¹, A. Lazzarin¹¹, A. Di Biagio¹², L. Gianserra¹³, A. Pennica¹³, B. Rossetti¹⁴, S. Modica¹⁴, A. De Luca¹⁴, P. Vittozzi¹⁵, P. Pavone¹⁵, G. Detorre¹⁵, G. Palmiero¹⁶, G. Borgia¹⁶, G. Nardini¹⁷, G. Guaraldi¹⁷, C. Mussini¹⁷, E. Schiaroli¹⁸, F. Baldelli¹⁸, G. Lapadula¹⁹, V. Pastore¹⁹, A. Gori¹⁹, S. La Monica²⁰, R. Cauda²⁰, L. Badia²¹, P. Viale²¹, R. Marino²², F. Sozio²³, G. Parruti²³, R. Corsini²⁴, G. Magnani²⁴, M.a. Carleo²⁵, G. Pellicano²⁶, G. Nunnari²⁶, S. Marinello²⁷, A.m. Cattelan²⁷, A. Trentalange²⁸, L. Marinaro²⁸, S. Bonora²⁸, S. Ferrara²⁹, T. Santantonio²⁹, A. Chiriani²⁵, A. Antinori², L. Sarmati¹, M. Andreoni¹ Con Il Patrocinio Della Società Italiana Malattie Infettive Simit</i>
355	P 42	Optimal viro-immunological response among patients starting antiretroviral therapy (ART) during primary HIV-1 infection (PHI) <i>A. Mondì¹, C. Pinnetti¹, I. Abbate², G. Rozera², M.m. Plazzi¹, I. Mastroso¹, R. Libertone¹, P. Lorenzini¹, M.r. Capobianchi², A. Antinori¹, A. Ammassari¹</i>
2	P 43	High-dose rosuvastatin significantly increases serum vitamin D concentration in HIV-infected patients on combination antiretroviral therapy <i>L. Calza¹, E. Magistrelli¹, V. Colangeli¹, M. Borderi¹, E. Rosselli Del Turco¹, L. Bussini¹, I. Bon², M.c. Re², P. Viale¹</i>
3	P 44	Statin treatment plus vitamin D supplementation significantly decrease serum levels of inflammation and coagulation markers in HIV-infected patients on combination antiretroviral therapy <i>L. Calza, E. Magistrelli, V. Colangeli, R. Manfredi, E. Rosselli Del Turco, L. Bussini, P. Viale</i>
25	P 45	Bloodstream infections in patients living with HIV infection in the recent cART era: did something change? <i>L. Taramasso¹, F. Liggieri¹, G. Cenderello², F. Bovis³, A. Mesini¹, B. Giannini⁴, M. Giacomini⁴, G. Cassola², C. Viscoli¹, A. Di Biagio⁵</i>
106	P 46	A Randomized, Crossover Study to Evaluate the Efficacy of Maraviroc in Reducing the Cardiovascular Risk in HIV viro-suppressed Patients. A Pilot, Explorative, Study <i>F. Baldelli¹, M. Pirro¹, E. Schiaroli¹, A. Alunno¹, F. Bagaglia¹, S. Bastianelli¹, V. Bianconi¹, O. Bistoni¹, S. Cipriani¹, V. De Angelis², E. Falcinelli¹, S. Pierucci¹, S. Gerli¹, P. Gresele¹, D. Francisci¹</i>
150	P 47	Age at acquisition of HIV affects the risk of comorbidities after 25 years of infection exposure <i>N. Riva¹, A. Malagoli¹, I. Franconi¹, A. Bianchi¹, P. Sorin², A. Streinu-cerce², E. Rossi³, M. De Rosa³, C. Mussini¹, G. Guaraldi¹</i>
194	P 48	Durability of raltegravir plus abacavir/lamivudine regimens in HIV-1-infected patients: the ORASWIRAL Study <i>L. Galli¹, A. Poli¹, C. Muccini^{1,2}, N. Galizzi^{1,2}, A. Danise¹, V. Spagnuolo², S. Salpietro¹, N. Gianotti¹, E. Carini¹, A. Lazzarin^{1,2}, A. Castagna^{1,2}</i>
257	P 49	Maraviroc Pharmacokinetics in HCV/HIV co-infected patients treated with DAAs <i>A. Barco¹, L. Marinaro¹, F. Patti¹, M. Merli², O. Bargiacchi³, C. Montrucchio¹, C. Alcantarini¹, F. Favata¹, A. Ariaudo¹, C. Costa¹, M. Tettoni¹, H. Hasson², A. D'avolio¹, C. Uberti-foppa², G. Di Perri¹, S. Bonora¹</i>
277	P 50	Virological Response and Resistance Profile in HIV-1 Infected Patients Starting a First-Line Regimen Containing a Protease Inhibitor or an Integrase Inhibitor in Clinical Practice <i>D. Redi¹, C. Spertilli Raffaelli¹, A. D'avino², M.c. Postorino³, A. Bezenchek⁴, R. Scutari⁵, A. Emiliozzi², M. Di Gaetano⁶, S. Barbaliscia⁵, I. Fanti², D. Di Carlo⁵, S. Di Giambenedetto², V. Borghi⁶, M. Zazzi⁷, M.m. Santoro⁵</i>
313	P 51	Incidence and predictors of drug changes in first-line cART show stability of regimens including integrase inhibitors notwithstanding complexity of factors and increased propensity to change over calendar years: results from the MASTER Cohort Study <i>E. Focà¹, M. Prosperi², F. Castelli¹, S. Casari¹, F. Maggiolo³, E. Di Filippo³, S. Di Giambenedetto⁴, F. Baragli⁵, N. Ladisa⁶, A. Gori⁷, L. Sighinolfi⁸, A. Pan⁹, C. Torti¹⁰ On Behalf Of Master Cohort Study Group</i>



Elenco Poster

ID	N. pgm	Title
237	P 52	Cerebrospinal Fluid EBV Replication is Associated with Compartmental Inflammation and Pleocytosis in HIV-positive naïve and Treated Individuals <i>T. Lupia¹, M.g. Milia², C. Atzori¹, S. Audagnotto¹, D. Imperiale³, A. Romito¹, S. Scabini¹, G. Gregori², F. Lipani¹, S. Bonora¹, G. Di Perri¹, A. Calcagno¹</i>
256	P 53	Outcome of HIV-associated Non Hodgkin Lymphomas presenting at HIV diagnosis or under antiretroviral treatment- Results from MULTICENTRIC STudy of HIV Associated Lymphomas (MUSTHAL study) <i>A. Bandera¹, L.verga², I. De Benedetto¹, E. Colella¹, E. Doni², A. Muscatello¹, N. Bianchetti², F. Crippa³, D. Dalu⁴, O. Giglio⁵, M. Mena⁶, D. Santoro⁵, E. Suardi³, P. Vitiello⁷, C. Zeroli⁷, A. Gori¹</i>
189	P 54	Alternate-day TDF/FTC/EFV single tablet regimen as maintenance therapy in virologically suppressed HIV individuals: results of the Day-On Day-Off (DODO) pilot study <i>C. Tontini¹, S. Agolini¹, M. Cognigni¹, A. Corsi¹, A. Marchionni¹, M. Martini¹, M. Rocchi¹, L. Butini², A. Costantini^{1,2}</i>
229	P 55	Efficacy and safety of switching to dolutegravir (DTG) plus tenofovir disoproxil fumarate (TDF) / emtricitabine (FTC) or elvitegravir (EVG) /cobicistat (COBI) / tenofovir disoproxil fumarate (TDF) / emtricitabine (FTC) in virologically suppressed (VS) HIV-infected patients in clinical practice: results from a multicenter, observational study <i>G. Baldin¹, A. Ciccullo¹, A. Borghetti¹, S. Lamonica¹, A. Capetti², M.v. Cossu², S. Rusconi³, L. Oreni³, G. Sterrantino⁴, F. Lagi⁴, A. Latini⁵, M. Colafigli⁵, A. Giacometti⁶, J. Vecchiet⁷, G. Caruana⁸, S. Di Giambenedetto¹ And G. Madeddu⁸</i>
231	P 56	Optimization strategies in a multicenter cohort of HIV1-infected, virologically suppressed patients: dual therapy (lamivudine + dolutegravir) vs Single Tablet Regimen (abacavir/lamivudine/dolutegravir) <i>G. Baldin¹, A. Ciccullo¹, A. Capetti², S. Rusconi³, G. Sterrantino⁴, G. Madeddu⁵, M.v. Cossu², T. Formenti³, F. Lagi⁴, M. Colafigli⁶, A. Freedman⁷, A. De Luca⁸, S. Di Giambenedetto¹</i>
287	P 57	Efficacy and Tolerability of dual therapy based on dolutegravir (DTG) and atazanavir/ritonavir (ATV/r) in the clinical setting <i>C. Alcantarini, M. Ferrara, L. Marinaro, B. Granozzi, M.c. Tettoni, C. Montrucchio, M. Milesi, A. Barco, C. Costa, G. Di Perri, S. Bonora</i>
297	P 58	Integrase strand-transfer inhibitors mutations in ART-naïve patients with acute/recent HIV-1 infection: exploring an evolving scenario <i>L. Lepore, C. Fabrizio, A. Leone, A. Lagioia, G. Punzi, A. Saracino, G. Angarano, L. Monno</i>
23	P 59	Dual unboosted atazanavir-lamivudine combination as maintenance treatment in virologically suppressed HIV-1-infected patients <i>F. Rigo¹, G. Cucchetto¹, M. Lanzafame¹, S. Nicolè¹, E. Lattuada¹, E. Concia¹, S. Vento^{2,3}</i>
58	P 60	Elevated serum uric acid levels impair endothelial function in HIV patients receiving antiretroviral therapy <i>D. Francisci¹, V. Bianconi², E. Schiaroli¹, M.r. Mannarino², F. Bagaglia², A. Sahebkar³, T. Merriman⁴, F. Baldelli¹, M. Pirro²</i>
91	P 61	Effect of Switching to Dolutegravir on HIV-DNA Levels and Residual Viremia in Patients with Suppressed HIV-RNA <i>F. Lombardi¹, S. Belmonti¹, R. Ricci², D. Speziale², E. Visconti¹, D. Moschese¹, A. Borghetti¹, R. Gagliardini¹, G. Baldin¹, A. De Luca^{3,4}, R. Cauda¹, S. Di Giambenedetto¹</i>
157	P 62	The disease burden associated with HIV associated chronic pulmonary disease exceed COPD diagnosis <i>A. Santoro¹, A. Malagoli¹, L. Wallace², M. Menozzi¹, M. Digaetano¹, N. Riva¹, I. Franconi¹, A. Raimondi¹, A. Bianchi¹, C. Mussini¹, G. Guaraldi¹</i>
197	P 63	Metabolic, renal and liver events related to EVG/COBI/FTC/TDF use in SCOLTA project: a real life experience <i>N. Squillace¹, E. Ricci², T. Quirino³, A. Gori¹, L. Carezzi², G.v. De Socio⁴, G. Orofino⁵, C. Martinelli⁶, F. Peruzzu⁷, S. Rusconi⁸, P. Maggi⁹, B.m. Celesia¹⁰, L. Cordier², F. Vichi¹¹, L. Calza¹², K. Falasca¹³, A. Di Biagio¹⁴, G.f. Pellicano¹⁵, P. Bonfanti¹⁶</i>
252	P 64	Efficacy and safety of the switch to dolutegravir-based dual therapy in HIV positive experienced patients <i>M. Giralda¹, E. Quiros², G. Paraninfo², F. Maggiolo³, E. De Filippo³, S. Digiambenedetto⁴, A. Gori⁵, N. Ladisa⁶, M. Di Pietro⁷, L. Sighinolfi⁸, A. Pan⁹, F. Castelnuovo¹⁰, N. Mazzini¹, G. Carosi¹ And The Master Study Group</i>
260	P 65	Atazanavir-based dual antiretroviral regimens in routine clinical practice <i>M. Colafigli¹, A. Borghetti², I. Fanti², G. D'ettore³, F. Di Sora⁴, G. Maffongelli⁵, E. Anzalone⁶, R. Marocco⁷, A. Pennica⁸, M. Scuderi⁹, M. Lichtner⁷, A. Cristaudo¹, C.m. Mastroianni⁷, M. Andreoni⁵, V. Vullo³, R. Cauda², A. Latini¹, S. Di Giambenedetto²</i>
264	P 66	Unmet needs of patients infected by HIV with HCV/HBV co-infections over a decade in Italy: results of the Italian MaSTER cohort <i>C. Torti¹, M. Prosperi², M. Giralda³, P. Nasta⁴, E. Quiros-rolan⁴, F. Maggiolo⁵, S. Di Giambenedetto⁶, A. Saracino⁷, M. Di Pietro⁸, L. Sighinolfi⁹, A. Gori¹⁰, S. Lorenzotti¹¹, M.c. Postorino¹, G. Carosi³</i>
324	P 67	The effect of switching to Darunavir/r + Maraviroc dual therapy in virologically suppressed patients on the progression of liver fibrosis: findings from a randomized study <i>B. Rossetti^{1,2}, R. Gagliardini², G. Sterrantino³, V. Colangeli⁴, A. Latini⁵, M.colafigli⁵, Vignale⁶, S. Rusconi⁷, A. Di Biagio⁸, G. Orofino⁹, I. Mezzaroma¹⁰, V. Vullo¹¹, D. Francisci¹², C. Mastroianni¹³, M. Trezzi¹⁴, B. Canovari¹⁵, A. D'armino Monforte¹⁶, S. Lamonica², D. Faliero², S. Di Giambenedetto², A. De Luca^{1,17} For Gusta Trial Study Group</i>
342	P 68	Prevalence of fragility vertebral fractures in a population of HIV-infected patients <i>S. Duranti¹, A. Londero¹, F. Vescini², N. Castaldo¹, F. Grimaldi², M. Bassetti¹</i>



Elenco Poster

ID	N. pgm	Title
347	P 69	Use of Integrase Strand Transfer Inhibitors (INSTIs) are not associated to Neurocognitive Impairment (NCI) in HIV positive persons <i>C. Pinnetti, I. Mastroianni, P. Lorenzini, P. Balestra, M. Ricottini, A. Mondì, V. Mazzotta, G. Fabbri, S. Cicalini, M. Zaccarelli, A. Ammassari, A. Antinori</i>
11	P 70	Dolutegravir plus rilpivirine dual regimen as a switch option in HIV-infected, cART-experienced subjects <i>A.f. Capetti¹, G.v. De Socio², M.v. Cossu¹, G. Sterrantino³, G. Barbarini⁴, S. Di Giambenedetto⁵, G.c. Orofino⁶, A. Di Biagio⁷, B.m. Celesia⁸, B. Argenterì¹, G. Rizzardini^{1,9}</i>
37	P 71	Diabetes and insulin resistance in HIV infected adults <i>F. Maggiolo¹, R. Teocchi², E. Di Filippo¹, L. Comi¹, A. Callegaro³, D. Valenti¹, M. Rizzi¹</i>
50	P 72	Correlates of neurocognitive impairment among chronically HIV-suppressed patients under treatment with tenofovir/emtricitabine/efavirenz: screening results from the SWEAR (Switch from Efavirenz/Atripla to Rilpivirine) Study <i>G. Lapadula¹, P. Tatarelli², E. Focà³, F. Bai⁴, S. Bonora⁵, A. Bandera¹, M. Bani⁶, M. Valsecchi⁶, M. Fabbiani¹, G. Di Perri⁴, A. Di Biagio², F. Castelli³, A. D'armino-monforte⁴, F. Conti⁶, M. Tosato², B. Saccani³, S. Compostella³ And A. Gori For The Swear Study Group^{1,6}</i>
83	P 73	Raltegravir plus lamivudine as "maintenance" therapy in suppressed HIV-1 infected patients in real life settings <i>G. Cucchetto¹, M. Lanzafame¹, S. Nicolè¹, E. Lattuada¹, L. Calza², E. Concia¹</i>
196	P 74	Long-term Immune Response to 13-Valent Pneumococcal Conjugate Vaccine versus 23-Valent Polysaccharide Vaccine In HIV-1 Infected Adults <i>F. Lombardi¹, S. Belmonti¹, B. Rossetti^{1,2}, S. Modica³, L. Paglicci³, S. Lamonica¹, R. Cauda¹, A. De Luca^{2,3}, F. Montagnani^{2,3}</i>
300	P 75	Virological and Immunological efficacy of Maraviroc-based regimens in experienced patients with undetectable HIV viral load <i>D. Redi¹, B. Rossetti^{1,13}, L.i. Bellazzi², I. Vicenti³, G. Colao⁴, G. Sterrantino⁵, L. Monno⁶, G. Punzi⁷, V. Borghi⁸, M. Pecorari⁹, S. Paolucci¹⁰, P. Meraviglia¹¹, V. Micheli¹², S. Di Giambenedetto¹³, M. Zazzi³, A. De Luca^{1,13}</i>
317	P 76	Durability and virological response to Dual and Mono Antiretroviral therapy in 45 HIV+ patients: a 5-years experience at Santa Maria Annunziata Hospital, Florence Area, 2012-2016 <i>F.m. Fusco¹, F. Vichi¹, A. Poggi¹, M.c. Burla², L. Rabatti², F. Baragli¹, A. Gabbuti¹, A. Degli Esposti¹, P. Pierotti¹, C. Blè, L. Mecocci¹, M. Di Pietro³, P. Blanc¹</i>
8	P 77	Durable viral control by boosted atazanavir or darunavir plus maraviroc (MVC) in poorly adherent subjects in view of long-acting regimens <i>A.f. Capetti¹, M.v. Cossu¹, N. Astuti¹, S. Landonio¹, F. Niero¹, S. Vimercati², G. Rizzardini^{1,3}</i>
48	P 78	Darunavir/cobicistat monotherapy in experienced HIV-1 positive subjects <i>G. Sterrantino, P. Rogasi, M. Trotta, A. Bartoloni</i>
77	P 79	Different Cell Cycle Modulation in SKOV-3 Ovarian Cancer Cell Line by Anti-HIV Drugs <i>M.a. Carleo¹, V. Sangiovanni¹, V. Iodice¹, A. De Luca², V. Esposito³, A. Chirianni¹</i>
400	P 80	Internet illiteracy as a barrier to web- based health promotion resource among elderly HIV patients <i>A. Caselgrandi¹, A. Malagoli¹, M. Mancini¹, V. Masi¹, E. Bardì¹, M. Corni¹, M. Menozzi¹, S. Zona¹, F. Carli¹, C. Mussini¹, L. Wallace², G. Guaraldi¹</i>
45	P 81	HIV Genotypic Drug Resistance test (GRT) for Integrase Strand Transfer Inhibitors (INSTIs) at low level viremia: light and shadow in the clinical practice <i>D. Mileto¹, D. Cattaneo², A. Mancon¹, A. Tamoni¹, L. Fiori¹, P. Meraviglia³, S. Rusconi⁴, M. Gismondo¹, V. Micheli¹</i>
170	P 82	Changes of lipid profile after switching to E/C/F/TAF: data from the Italian Compassionate Use Program <i>A. Vergori¹, G. Fabbri¹, P. Lorenzini¹, M. Plazzi¹, G. Maffongelli², C.cerva², P. Vitiello³, T. Quirino³, R. Rossotti⁴, E. Danieli⁴, P. Tau⁴, M. Puoti⁴, P. Lanza⁵, F. Castelli⁵, M. Trizzino⁶, A. Cascio⁶, P. Costenaro⁷, V. Manfrin⁷, R. Ferretto⁷, M. Colafigli⁸, A. Latini⁸, C. Cristaudo⁸, L. Gianserra⁹, A. Pennica⁹, B. Rossetti¹⁰, S. Modica¹⁰, A. De Luca¹⁰, G. Nardini¹¹, G. Guaraldi¹¹, C. Mussini¹¹, E. Schiaroli¹², F. Baldelli¹², G. Lapadula¹³, V. Pastore¹³, A. Gori¹³, S. La Monica¹⁴, R. Cauda¹⁴, L. Badia¹⁵, P. Viale¹⁵, R. Corsini¹⁶, G. Magnani¹⁶, M.a. Carleo¹⁷, G. Pellicano¹⁸, G. Nunnari¹⁸, A. Chirianni¹⁷, M. Andreoni², A. Antinori¹ Con Il Patrocinio Della Società Italiana Di Malattie Infettive E Medicina Tropicale</i>
232	P 83	NRTI-sparing regimens: renal safety <i>P. Colletti¹, A. Cervo¹, G. Mazzola¹, M. Trizzino¹, M. Mineo¹, L. Adamoli¹, P. Di Carlo¹, D. Matranga², A. Cascio¹</i>
251	P 84	Management of diabetes mellitus among HIV-infected patients in an Italian cohort <i>F. Castelnuovo, A. Bergamasco</i>
281	P 85	Characteristics and viro-immunological outcomes of HIV-infected patients aged >65 years: a retrospective monocentric study <i>A. Emiliozzi, R. Gagliardini, A. Borghetti, G. Baldin, D. Moschese, D. Faliero, A. Ciccullo, S. Lamonica, R. De Marco, A. Brita, S. Belmonti, F. Lombardi, R. Cauda, S. Di Giambenedetto</i>
291	P 86	Retrospective observational study on efficacy of TDF/FTC+DTG as a first-line therapy versus other recommended first line therapies in clinical practice <i>F. Del Puente, P. Tatarelli, E. Balletto, N. riccardi, F. Magnè, A. Di Biagio</i>



Elenco Poster

ID	N. pgm	Title
318	P 87	Trimethylamine-N-oxide Serum Concentrations in HIV-positive Treated Patients <i>C. Costa, C. Montrucchio, D. Pensi, S. Sburlati, C. Alcantarini, A. Barco, M. Ferrara, M. Milesi, A. Trentalange, M.c. Tettoni, A. D'avolio, S. Bonora, G. Di Perri, A. Calcagno</i>
366	P 88	Patients with sub-adherence to HAART: how to identify them to prevent therapy failures? <i>G. Orofino², M. Guastavigna², C. Carcieri¹, S. Bertini³, D. Piccioni³, S. Carosella², M. Farenga², G. Cinnirella³, P. Caramello²</i>
394	P 89	Statin need and protease inhibitors: harm or a clinical opportunity? <i>S. Zona, F. Carli, M. Menozzi, B. Beghetto, G. Nardini, A. Santoro, C. Mussini, G. Guaraldi</i>
413	P 90	Antiretroviral dual regimens sparing agents from boosted (RTV or Cobi)-protease inhibitor class and integrase strand transfer inhibitors (ISTIS) class <i>A. Mastroianni¹, E. Briganti¹, F. Allegrini¹, C. Grosso¹, S. Brighi¹, S. Di Cesare¹, G.f. Ravaglia², F. Pieraccini², C. Cancellieri¹</i>
104	P 91	Boosted darunavir plus dolutegravir as salvage or simplification of salvage therapy: 48 weeks' data <i>A.f. Capetti¹, G. Orofino², G. Sterrantino³, A. Soria⁴, G. Cenderello⁵, M.v. Cossu¹, A.m. Cattelan⁶, G.v. De Socio⁷, S. Rusconi⁸, N. Riccardi⁹, G.m. Baldin⁹, G. Barbarini¹⁰, F.p. Niero¹, G. Rizzardini^{1,12}</i>
206	P 92	CCR5 inhibitor based antiretroviral therapy and liver fibrosis progression in HIV positive patients (MAICOL study final and post-hoc analysis) <i>P. Nasta¹, E. Chiari¹, F. Gatti², M. Giralda³, F. Pasotti⁴, D. Ricotta⁴, G. Carosi³, F. Castelli¹</i>
280	P 93	Management and prevention of dolutegravir-related insomnia <i>A.f. Capetti¹, I. De Benedetto², G.m. Baldin³, A. Latini⁴, G. Sterrantino⁵, S. Landonio¹, M.v. Cossu¹, F.p. Niero¹, N. Astuti¹, L. Valsecchi¹, P. Meraviglia¹, S. Di Giambenedetto³, A. Gori², G. Rizzardini^{1,6}</i>
288	P 94	Hypophosphatemia is not a predictive marker of impaired bone mineral density: a cross sectional study <i>M. Maritati¹, V. Guardigni^{2,3}, D. Segala³, L. Sighinolfi³</i>
296	P 95	Prevalence and correlates of transaminitis in HIV-1 infected patients in the absence of HCV and HBV infection <i>C. Resnati¹, V. Morena¹, E. Gervasi¹, S. Limonta¹, L. Oreni¹, A. Riva²</i>
337	P 96	How maraviroc was prescribed in routine clinical practice and what impact of fibrosis or inflammation markers? <i>P.m. Concetta¹, C. Torti¹, P. Nasta², E. Quiros-rolan², F. Maggiolo³, S. Di Giambenedetto⁴, A. Saracino⁵, M. Pietro⁶, L. Sighinolfi⁷, A. Gori⁸, S. Lorenzotti⁹, G. Carosi¹⁰</i>
113	P 97	A comparison of 2-year durability of efavirenz and rilpivirine based regimens in clinical practice: data from the ICONA Foundation cohort <i>A. Di Biagio¹, L. Taramasso², A. Cozzi-Iepri³, F. Maggiolo⁴, A. Tavelli⁵, S. Lo Caputo⁶, S. Bonora⁷, M. Zaccarelli⁸, P. Caramello⁹, A. Costantini¹⁰, C. Viscoli², A. D'arminio¹¹</i>
124	P 98	Assessment of appropriateness of first-line combined antiretroviral treatment (cART): the preliminary results of Liguria experience V. E.L.A. study <i>G. Cenderello¹, A. Di Biagio², F. Artom¹, C. Dentone³, V. Bartolacci⁴, P. De Leo⁵, M. Anselmo⁵, M. Guerra⁶, B. Giannini⁷, P. Orcamo⁸, S. Artioli⁶, G. Ferrea³, G. Riccio⁴, M. Anselmo⁵, M. Giacomini⁷, G. Cassola¹, C. Viscoli²</i>
341	P 99	Pure red cells aplasia due to parvovirus-B19 chronic infection in HIV-HCV co-infected patients. Report of two cases <i>F. Sabbatini, I. De Benedetto, M. Fabbiani, A. Soria, S. Trovati, A.m. Peri, A. Dolara, L. Bisi, A. Cappelletti, E. Colella, A. Bandera, A. Gori</i>
41	P 100	Darunavir/ritonavir at reduced dosage of 600mg/100 mg once daily in a short numbers of heavily experienced HIV-1 positive patients <i>E. Lattuada, M. Lanzafame, S. Nicolè, F. Rigo, G. Cucchetto, E Concia</i>
244	P 101	Low dose of unboosted atazanavir plus dolutegravir as simplification strategy for HIV-infected patients receiving antiretroviral therapy <i>E. Pontali, A. Torresin, G. Cenderello, M. Feasi, M.p. Crisalli, G. Penco, N. Bobbio, G. Cassola</i>
270	P 102	Management of comorbidities in HIV-infected population: results of a multicenter survey in Italy <i>A. Borghetti¹, M. Colafigli², N. Coppola³, A. Costantini⁴, O. Cirioni⁵, Di Biagio⁶, F. Di Sora⁷, M. Fabbiani⁸, S. Ferrara⁹, A. Giacometti⁵, A. Latini², A. Maddaloni¹⁰, M. Maritati¹¹, M. Martini⁴, G. Orofino¹², A. Pennica¹³, D. Penoncelli¹², C. Resnati¹⁴, S. Rusconi¹⁴, L. Sighinolfi¹¹, G. Sterrantino¹⁵, L. Taramasso⁶, M. Zazzi¹⁶, S. Di Giambenedetto¹, A. De Luca¹⁷ For The Ecco Group</i>
21	P 103	Dolutegravir monotherapy in HIV-infected naive patients with <100,000 copies/ml HIV-RNA load: a long-term follow-up <i>M. Lanzafame^{1,3}, S. Nicolè³, D. Gibellini², E. Lattuada³, G. Cucchetto³, F. Rigo³, E. Diani², E. Concia³, S. Vento^{4,5}</i>
53	P 104	Efficacy and safety of lipid-lowering therapy in the treatment of patients with HIV disease and hypercholesterolemia: A 20 YEARS single-centre retrospective study <i>A. Mastroianni, F. Allegrini, E. Briganti, S. Di Cesare, C. Grosso, C. Antonini, S. Brighi</i>



Elenco Poster

ID	N. pgm	Title
79	P 105	An uncommon localization of non-Hodgkin lymphoma in a HIV patient under successful antiretroviral therapy: a case report of an endobronchial cancer <i>O. Tambaro¹, G. Bonadies¹, A.e. Maraolo¹, G. Palmiero¹, F. Borrelli¹, G. Di Filippo¹, U. Caterino², G. Borgia¹</i>
292	P 106	Tuberculosis-related IRIS masking cerebral cryptococcoma. A case report <i>S. Coladonato, F. Volpato, A. Cascavilla, E. Magistrelli, M. Tadolini, S. Ianniruberto, R. Pascale, L. Marconi, G. Virgili, N. Rossi, P. Viale</i>
396	P 107	Evaluation of cardiovascular risk in HIV positive patients under HAART <i>S. Lardo, K. De Gaetano Donati, V. Mazzotta, V. Mazzocato, M. Olivieri, S. Costanzo, A. De Curtis, L. Iacoviello, E. Tamburrini, R. Cauda</i>
30	P 108	"High" antiretroviral deintensification: a case series <i>M. Lanzafame^{1,3}, R. Gottardo², S. Nicolè³, E. Lattuada³, G. Cucchetto³, F. Rigo³, E. Concia³, F. Tagliaro², S. Vento^{4,5}</i>
43	P 109	Evaluation of HIV-RNA decay, HIV-DNA and inflammation markers modification in a cohort of twenty HIV-1 infected naive patients treated with ABC/3TC/DTG <i>S. Nicolè¹, M. Lanzafame¹, E. Lattuada¹, R. Mazzi¹, F. Rigo¹, G. Cucchetto¹, D. Gibellini², E. Diani², E. Concia¹</i>
72	P 110	Monitoring requirements in antiretroviral-naïve patients: the experience of INMI Spallanzani in Rome <i>F. Ferrara, M. Rizzica, S. Murachelli, A. Antinori, A. Ascani, G. Zaccaro, B. Moreno, L. Chiroso, M. Carli</i>
121	P 111	Pharmacokinetics of darunavir/cobicistat in an Italian observational, multicenter, prospective study (The STart Of REzolsta "ST.O.RE" study - TMC114FD1HTX4003) <i>A. Gori¹, E. Focà², A. Antinori³, A. Vergori³, R. Maserati⁴, S. Rusconi⁵, V. Di Cristo⁵, A. Uglietti⁶, R. Termini⁶, D. Mancusi⁶</i>
151	P 112	Cardiovascular risk in HIV+ patients: 2006 - 2016 Vasto Infectious Diseases experience <i>S. Antonelli, M.p. Sciotti</i>
349	P 113	Efficacy and safety of Dolutegravir-based combination antiretroviral therapy in clinical practice in naive HIV-infected patients: results from a multicenter study <i>G. Caruana¹, G. Madeddu¹, P. Bagella¹, F. Clark², G. Nunnari³, G. Pellicanò³, G. Angioni⁴, M. Sedda⁵, A. De Vito⁶, S. Babudieri¹, A. Freedman⁷</i>
303	P 114	Hepatic safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in patients with pre-existing hepatic comorbidities <i>E. Francalanci¹, L. Badia^{1,2}, V. Guardigni^{1,2}, L. Bussini¹, P. Viale¹, G. Verucchi^{1,2}</i>

Coinfections/sexually transmitted infections

134	P 115	Prevalence of quadrivalent and nonavalent Human Papillomavirus vaccine genotypes among HIV-infected men who have sex with men in Rome, Italy <i>M.g. Donà¹, A. Latini¹, M. Colafigli¹, M. Benevolo², F. Rollo², M. Zaccarelli³, D. Moretto⁴, A. Giglio⁴, A. Cristaudo¹, M. Giuliani¹</i>
328	P 116	Effect of HCV eradication on specific CMV response in HCV+ and HCV/HIV subjects undergoing DAAs <i>S. Vita¹, C. Mascia¹, P. Zuccalà¹, O. Turriziani¹, R. Marocco², I. Pozzetto², C. Ajassa¹, M. Lichtner², C.m. Mastroianni², V. Vullo¹</i>
284	P 117	High/Low Risk HPV genotype distribution and persistence in HIV positive and negative patients <i>M. Statzu¹, I. Sciandra¹, I. Tino¹, C. Bitossi¹, G. De Girolamo², I. Schietroma², E.n. Cavallari², M. Gentile¹, G. Antonelli¹, C. Scagnolari¹, A. Pierangeli¹, G. D'ettore²</i>
135	P 118	Abnormal anal cytology among HIV-infected men who have sex with men: prevalence and predictors <i>M.g. Donà¹, M. Benevolo², A. Latini¹, M. Colafigli¹, M. Zaccarelli³, F. Rollo², A. Giglio⁴, D. Moretto⁴, A. Cristaudo¹, M. Giuliani¹</i>
390	P 119	European outbreak of Hepatitis A in MSM population: our experience in Padua General Hospital <i>G. Marini, A. Celotti, D. Coletto, S. Marinello, A. Cattelan</i>
27	P 120	Outbreak of Hepatitis A among men who have sex with men in Umbria <i>L.m. Saraca¹, C. Di Giuli², A.r. Ciccaglione³, G. Priante⁴, B. Tiri⁵, D. Francisci⁶</i>
345	P 121	Screening of papillomavirus infection (HPV) and anal cancer in MSM HIV positive in Sanremo Hospital <i>I. De Macina¹, C. Dentone¹, P. Quilici², P. Secondo³, A. Dusi⁴, G. Ferrea¹</i>
175	P 122	Prevalence and sociodemographic correlates of hepatitis B and C coinfection and triple infection among People Living with HIV: a seven year retrospective data review of rural HIV Clinic in Northern Nigeria <i>V. Adepoju, V. Okafor, C. Ogbudebe, C. Ekerete-udofia</i>
110	P 123	Screening for HBV, HCV and Treponema pallidum infections in HIV-positive patients in north-west of Benin, Africa <i>C. Ceriani¹, S. Cavallari¹, T. Cerulli¹, C. Debora¹, M. De Paschale¹, K. Diombo², J. Ndayake², P. Viganò³, P. Clerici¹</i>



Elenco Poster

ID N. pgm Title

Gender issues

- 33 P 124** Gender differences in retention in care in a prospective cohort of HIV-infected adults in Tigray, Ethiopia
R. Bucciardini¹, P. Tatarelli², V. Fragola¹, T. Abegaz³, S. Lucattini¹, A. Halifom⁴, E. Tadesse³, M. Berhe³, K. Pugliese¹, P. De Castro¹, R. Terlizzi¹, L. Fucili¹, M. Di Gregorio¹, M. Mirra¹, T. Zegeye⁴, A. Giammarioli¹, S. Vella¹, L. Abraham³, H. Godefay, The Casa-project Health Facilities⁴
- 310 P 125** Switch from PI/r based therapy to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir in a cohort of women with HIV infection and stable antiretroviral therapy: Retrospective analysis of efficacy and tolerability after 48 weeks
R. Pennone, A. Maddaloni, A. Busto, P. Rosario, M. D'abbraccio, V. Esposito
- 74 P 126** Non-filter love. Forms and causes of barebacking
G. Fracca, A. Bianchi, M. Cernuschi, M. Lanza

Hepatitis Clinical diagnostics and pathogenesis

- 153 P 127** Partial recovery of peripheral T cell homeostasis following successful treatment with direct antiviral agents (DAA) in HIV/HCV co-infected patients
M. Chiamenti, F. Bai, R. Curetti, A. De Bona, G. Marchetti, A. D'armino Monforte
- 325 P 128** Monitoring DAAs treatment for chronic hepatitis C by quantitative HCV RNA and HCV core Antigen assays
S. Mercinelli¹, B. Rossetti^{1,2}, C. Gandolfo³, M. Pomi¹, R. Salviati¹, G. Lentini³, A. De Luca^{1,4}, M.g. Cusi³
- 363 P 129** Urinary metabotypes in patients with chronic hepatitis C virus infection as revealed by nuclear magnetic resonance-based metabolomics
E. Biliotti¹, A. Tomassini², D. Palazzo¹, G. Capuani², F. Sciubba², R. Esvan¹, M. De Angelis¹, C. Franchi¹, G. Iaiani¹, P. Maida¹, M. Spaziante¹, A. Miccheli², G. Taliani¹
- 103 P 130** High rate of misclassification of advanced fibrosis using APRI and Fib-4 in a cohort of HIV/HCV patients
L. Adamoli¹, G. Mazzola¹, V. Calvaruso², P. Colletti¹, A. Cervo¹, M. Trizzino¹, P. Di Carlo¹, S. Corrao³, F. Di Lorenzo³, T. Prestileo³, A. Sanfilippo³, V. Di Marco², A. Cascio¹
- 102 P 131** Marked Reduction of Adiponectin, Selenoprotein P and Fetuin A in HCV-infected Patients Treated with IFN-free Regimens
P. Pavone¹, G. D'ettorre¹, I. Schietroma¹, G. Corano-scheri¹, S. Najafi-fard¹, C. Pinacchio¹, C. Mascia¹, T. Tieghi², M. Lichtner², C. Mastroianni², V. Vullo¹
- 263 P 132** In Vitro Effect of Direct-Acting Antivirals (DAA) and Antiretroviral Drugs on Cell Toxicity and Matrix Metalloproteinase Inhibition in LX-2 Hepatic stellate Cells
I. Pati¹, T. Latronico¹, C. Mascia², F. Mengoni², A. Fasano¹, A. Zingaropoli², M. Lichtner^{2,3}, V. Vullo², C.m. Mastroianni^{2,3}, G.m. Liuzzi¹

Hepatitis Epidemiology

- 216 P 133** Epidemiology and risk factors for HCV genotypes in a high prevalence region
R. Scotto¹, A.r. Buonomo¹, B. Pinchera¹, M. Crispo¹, C. Monari², M. Macera², S. De Pascalis², G. Di Filippo¹, F. Borrelli¹, N. Coppola², I. Gentile¹, G. Borgia¹
- 163 P 134** Acute HCV, HAV or HEV in HIV+ men having sex with men: a three years retrospective study in a single center of Emilia-Romagna
A. Mastroianni¹, F. Allegrini¹, E. Fiumana², P. Billi³, M. Della Strada³, S. Semprini³, V. Sambri³
- 147 P 135** Epidemiological and Phylogenetic study of HBV in Migrant People in the South of Italy (Calabria region)
F. Bulla, S. Lombardo, S. Ambrosio, G. Sirianni, N. Careri, L.a. Surace

HIV Clinical diagnostics and pathogenesis

- 261 P 136** Resistance detected in PBMC GRT predicts virological rebound in HIV-1 suppressed patients switching treatment
D. Armenia¹, M. Zaccarelli², V. Borghi³, W. Gennari³, D. Di Carlo¹, A. Giannetti², F. Forbici², A. Bertoli¹, C. Gori², L. Fabeni², C. Pinnetti², R. Marocco⁴, A. Latini⁵, F. Ceccherini Silberstein¹, C.m. Mastroianni⁴, C. Mussini³, A. Antinori², C.f. Perno², M.m. Santoro¹
- 391 P 137** Effects of treatment with Maraviroc a CCR5 inhibitor on a human hepatic stellate cell line
S. Martini¹, A. Perna², A. Lucariello², M. Macera¹, M.a. Carleo³, G. Guerra⁴, V. Esposito⁵, A. De Luca², N. Coppola¹
- 80 P 138** Calculation of the Avidity Index for anti-HIV antibodies on a cohort of Western blot (WB)-reactive samples
M. Aquilina¹, C. Colomba², D. Mililli², F. Bonura¹, G.m.e. Colomba¹, G.m. Giammanco¹, A. Cascio²
- 143 P 139** Performance of new end-to-end assay for HIV-1 Sanger sequencing
I. Bon, G. Musumeci, S. Longo, A. Bertoldi, V. D'urbano, C. Fazio, C. Coppola, M.c. Re
- 148 P 140** Application of Sigma metrics for the assessment of precision in HIV viral load testing: an experience in the routine of a high throughput laboratory
A. Amendola¹, P. Piselli², M. Pisciotta¹, M. Paterno¹, M.r. Capobianchi¹



Elenco Poster

ID	N. pgm	Title
326	P 141	Metabolic activity of lymphoid tissue evaluated using PET in acute HIV infection and long-term evolution of CD4/CD8 ratio <i>A. Bonazza¹, S. Zona¹, M. Menozzi¹, A. Santoro¹, M. Digaetano¹, A. Raimondi¹, V. Borghi¹, G. Guaraldi¹, N. Prandini², C. Mussini¹</i>
365	P 142	Missed opportunities for earlier HIV diagnosis in late-presenting patients: a cohort study at an Italian HIV center during the period 2011-2016 <i>L. Van Den Bogaart, A. Ranzani, L. Oreni, G. Bozzi, C. Resnati, S. Antinori, M. Galli, A.I. Ridolfo</i>
97	P 143	Comparison of genotypic and phenotypic drug susceptibility evaluation of a rare case of multidrug resistant HIV-1 <i>F. Saladini¹, A. Giannini¹, A. Martini¹, A. Poggi², F. Vichi², B. Del Pin², A. Boccutto¹, I. Vicenti¹, M. Di Pietro², M. Zazzi¹</i>
14	P 144	Prevalence of cytological abnormalities and HPV infection in anal samples collected by anal swab among HIV-infected men who have sex with men referring to a large outpatient clinic <i>E. Magistrelli¹, L. Calza¹, V. Colangeli¹, G. Policastro¹, E. Rosselli Del Turco¹, L. Bussini¹, N. Rossi¹, S. Venturoli², L. Prosperi³, P. Viale¹</i>
376	P 145	TM6SF2 E167E variant is associated with higher serum cholesterol values and carotid intima-media thickness in patients with HIV infection <i>G. Di Caprio¹, S. Martini¹, A. Cascone¹, C. Sagnelli³, M. Starace³, N. Farella², G. De Stefano², C. Uberti Foppa⁵, H. Hasson⁵, G. Cirillo⁴, L. Alessio¹, E. Miraglia De Giudice⁴, A. Lazzarin⁵, N. Coppola^{1,3}</i>
274	P 146	Role of FDG-PET/CT in patients with Kaposi sarcoma: a first retrospective analysis <i>A. Borghetti¹, S. Annunziata², M. Camici¹, V. Rufini², S. Di Giambenedetto¹</i>
56	P 147	COPD screening program in a HIV outpatient clinic of northern Italy <i>E. Quiros-roland¹, M.c. Pezzoli¹, A. Ferraresi¹, E. Raffetti², N. Brianese¹, P. Lanza¹, E. Focà¹, A. Bonito¹, I. Izzo¹, C. Chirico¹, F. Castelli¹</i>
139	P 148	Comparative evaluation of the Aptima® HIV-1 Quant Dx Assay and Roche CAP/CTM HIV-1 v2.0 for HIV-1 RNA Viral Load Detection and Quantitation in Plasma Samples of HIV-1-Infected Patients <i>S. Longo, I. Bon, G. Musumeci, A. Bertoldi, V. D'urbano, M.c. Re</i>
212	P 149	Evaluation of the new commercial Duplica-RealTime HLA-B*5701 EZ Type test for the HLA-B*5701 typing <i>T. Allice¹, B. Bruzzone², M.g. Milia¹, E. Burdino¹, G. Gregori¹, T. Ruggiero¹, B. Simoncelli¹, N. Nigro², R. Barresi², M. Zazzi³ And V. Ghisetti¹ And The Italian Hla-b*5701 Network</i>
236	P 150	Evaluation of cardiovascular risk in HIV+ subjects following 3 different algorithms <i>P. Vassalini¹, E.n. Cavallari¹, F. Vullo², M. Mancone³, S. Strano⁴, G. Ceccarelli⁵, G. D'ettore¹, V. Vullo¹</i>
248	P 151	Switch to EVG/c/TAF/FTC in virologically-suppressed patients does not seem to have an effect on immune activation and T cell differentiation <i>V. Bordon¹, O. Forini¹, G. Fabbri¹, M.m Plazzi¹, A. Vergori¹, G. Maffongelli², R. Bellagamba¹, M. Andreoni², A. Ammassari¹, A. Antinori¹, C. Agrati¹</i>
HIV Epidemiology and prevention		
209	P 152	Late presenters and young foreigners among heterosexuals with a new HIV diagnosis in Italy, 2010-2015 <i>V. Regine¹, L. Pugliese¹, B. Suligo¹, And The Regional Representatives Of The National Hiv Surveillance System*</i>
84	P 153	The Role of ART Simplification in Clinical Practice: Analysis of 143 Patients Followed at Two Italian Sites <i>S. Mazzanti¹, Z. Pasquini¹, V. Barocci¹, F.trave¹, O. Cirioni¹, A. Giacometti¹, M. Balducci², B.canovari², F. Barchiesi³</i>
402	P 154	Correlation between higher incidence of comorbidities and more frequent recourse to dual antiretroviral regimens in a cohort of HIV aged patients compared to younger one: analysis of retrospective cross-sectional study <i>S. Martini, N. Coppola, A. Cascone, P. Filippini</i>
108	P 155	Low prevalence of transmitted HIV-1 drug resistance in north-west of Benin, Africa <i>C. Ceriani¹, S. Cavallari¹, T. Cerulli¹, C. Debora¹, M. De Paschale¹, K. Diombo², J. Ndayake², P. Viganò³, P. Clerici¹</i>
378	P 156	AIDS home care service: past, present and future <i>M. Trezzi, M. Giorgi, B. Menichini, S. Bonelli, M. Benvenuti, C. Fabbri, D. Messeri, M. Uberti, A. Vivarelli, F. Esperti, M. Di Pietro</i>
315	P 157	PrEP as a preventive measure: what healthcare providers think about it. A qualitative research <i>F. Debbia¹, L. Badia², P. Viale², M. Libanore³, L. Sighinolfi³, C. Mussini⁴, N. Assueri¹</i>
388	P 158	Vaccination of HIV + patients: increase of adherence in a infectious diseases surgery <i>V. Frumento², A. Beltrame¹, P. De Leo¹, E.n. Malfatto¹, M. Marturano¹, P. Briata², M. Anselmo¹</i>
109	P 159	HIV Prevention in the Immigrants Day Hospital of Perugia <i>G. Gamboni, M. Damiani, C. Sfara, B. Marchini</i>



Elenco Poster

ID N. pgm Title

Immunology

- 306 P 160** HIV-1 reservoir is controlled by transcriptionally unique NK cells and associates directly with their CD335 CD337 inducibility and IFN- γ production
F. Marras^{1,2}, A. Casabianca⁴, F. Bozzano^{1,3}, M.I. Ascierto^{5,6}, C. Orlandi⁴, A. Di Biagio⁷, E. Pontali⁸, C. Dentone⁹, G. Orofino¹⁰, L. Nicolini^{7,11}, L. Taramasso¹¹, M. Magnani⁴, F.m. Marincola¹², E. Wang¹², L. Moretta¹³, A. De Maria^{1,7,11}
- 373 P 161** L/M and M/L blood RATIO in tuberculosis and HIV patients: comparative analysis, preliminary data
P. Di Carlo¹, N.r. Caccamo², G. Guadagnino¹, A. Cascio¹
- 122 P 162** Tryptophan metabolism in HIV-1 infected patients: the role of probiotics on gut-brain axis
G. Corano Scheri¹, I. Schietroma¹, E. Nelson Cavallari¹, S. Najafi Fard¹, C. Pinacchio¹, G. De Girolamo¹, C. Selvaggi², G. Fanello³, L. Laghi⁴, G. Ceccarelli⁵, C. Scagnolari^{2,6}, V. Vullo¹, G. D'ettorre¹
- 68 P 163** Vitamin D deficiency and gut inflammation in a cohort of HIV infected patients naive to Antiretroviral Therapy (ART)
V. Cogliandro¹, L. Gazzola¹, G. Ancona¹, E. Borghi², F. Borgo², N. Iannotti¹, T. Bini¹, G. Marchetti¹, A. D'armino Monforte¹

Neuropathogenesis and neurologic complications

- 141 P 164** Control beliefs and anxiety are associated to HIV progression during successful ART
N. Ciccarelli¹, R. Gagliardini¹, R. De Marco¹, A. Brita¹, S. Lamonica¹, E. Visconti¹, E. Tamburrini¹, A. Cingolani¹, A. De Luca^{1,2}, S. Di Giambenedetto¹
- 253 P 165** Cerebrospinal fluid (CSF) biomarkers of immune activation and brain cell injury in HIV-infected patients with CSF viral escape syndrome
V. De Zan, F. Ferretti, L. Passeri, D. Mennona, E. Tuveri, A. Lazzarin, P. Cinque
- 250 P 166** Clinical manifestations and outcomes in patients with neurosymptomatic cerebrospinal fluid viral escape syndrome
F. Ferretti¹, V. De Zan¹, E. Tuveri¹, N. Gianotti¹, A. Boschini², A. Lazzarin¹, P. Cinque¹
- 377 P 167** Blood Brain Barrier (BBB) damage is associated with an increased intratecal immune activation, but not with neuronal injury in HIV-infected patients
C. Pinnetti, V. Fedele, S. Carta, M. Tempestilli, P. Lorenzini, I. Mastroiosa, A. Vergori, S. Grisetti, F. Baldini, C. Agrati, A. Ammassari, C.f. Perno, A. Antinori
- 191 P 168** CSF cytokine profile and blood brain barrier damage in HIV+ patients: role of HCV infection
V. Bordoni¹, C. Pinnetti¹, V. Fedele¹, S. Carta¹, A. Sacchi¹, P. Lorenzini¹, A. Ammassari¹, C.f. Perno^{1,2}, C. Agrati¹, A. Antinori¹
- 218 P 169** HIV Central Nervous System (CNS) escape/compartimentalization: correlation with plasma viral load and blood brain barrier damage
D.f. Bavaro, A. Calamo, R. Dell'acqua, M. Mariani, A. Saracino, L. Monno, G. Angarano
- 374 P 170** Predictors of cognitive disorders in HIV-infected people: a 5-years follow-up study
N. Ciccarelli¹, A. Borghetti¹, A. Brita¹, R. De Marco¹, M. Fabbiani², R. Gagliardini¹, A. Ciccullo¹, A. De Luca^{1,3}, R. Cauda¹, S. Di Giambenedetto¹
- 405 P 171** Central nervous system symptoms, mood disorders and sleep disturbances are associated with reduced quality of life among patients under long-term suppressive treatment including efavirenz: screening results from the SWEAR (Switch from Efavirenz/Atripla to Rilpivirine) Study
G. Lapadula¹, F. Conti², M. Tosato³, M. Valsecchi², S. Compostella⁴, T. Bini⁵, M. Milesi⁶, M. Rossi¹, B. Saccani⁴, A. Di Biagio³, F. Bai⁵, M. Bani², E. Focà⁴, M. Fabbiani¹, S. Bonora⁶, A. Bandera¹, F. Castelli⁴, G. Di Perri⁶, A. D'armino-monforte⁵, C. Viscoli³, A. Gori^{1,2} For The Swear Study Group
- 354 P 172** Role of B12 vitamin and homocysteine levels in HIV-positive patients with neurocognitive disorders
K. Falasca, C. Ucciferri, F. Vignale, R. Piarulli, G. Ruggieri, P. Carboni, A. Occhionero, L. Caiazza, J. Vecchiet

Opportunistic infections

- 138 P 173** CD4+ T-cell immune response against immunogenic JCV-VP1 peptides with PML-associated mutations
L. Passeri¹, D. Mennonna¹, J. Sydney⁴, A. Sette⁴, F. Ferretti¹, A. Lazzarin³, G. Casorati², P. Dellabona², P. Cinque¹
- 305 P 174** The overlap between tuberculosis and HIV infection: a regional estimate in the last decade
P. Scognamiglio¹, A. Mammone¹, M. Sanè Schepisi¹, M. D'amato¹, G. Ferrara², V. Puro¹, V. Panella², G. Ippolito¹, E. Girardi³
- 321 P 175** Baseline screening for Latent Tuberculosis Infection in people living with HIV in a low TB incidence setting
S. Ianniruberto, E. Rosselli Del Turco, V. Guardigni, M. Tadolini, L. Calza
- 393 P 176** Risk of reactivation of latent Toxoplasmosis in an HIV-infected population
F. Brandolino, G. Iaiani, L. Fontanelli Sulekova, S. Gabrielli, G. Milardi, M. Spaziante, G. Taliani
- 368 P 177** Salvage therapy with I-amphotericin B, miltefosine, fluconazole, allopurinol and aerosolized pentamidine for disseminated mucocutaneous and visceral leishmaniasis in HIV disease
A. Mastroianni¹, S. Varani², F. Allegrini¹, E. Fiumana³, R. Zanelli⁴, E. Briganti¹, S. Di Cesare¹, C. Grosso¹, S. Brighi¹, P. Billi⁵, V. Sambri⁵



Elenco Poster

ID	N. pgm	Title
55	P 178	Progressive multifocal leukoencephalopathy in a patient with visceral Kaposi Sarcoma treated with liposomal doxorubicin <i>L.m. Saraca¹, A. Lavagna¹, L. Ruggeri², G. Priante¹, B. Tiri¹, C. Di Giuli¹, D. Francisci¹</i>
99	P 179	Changing incidence of Opportunist Infections (OIs) in the era of antiretroviral combination therapy (HAART), observational study <i>E.a. Piga¹, M. Motzo², M.ligas², S. Piga¹</i>
Pediatric, adolescent, maternal, fetal aspects		
269	P 180	Effectiveness of "Task Shifting" from clinical officers to nurses in delivering pediatric antiretroviral treatment: a retrospective cohort study in Beira (Mozambique) <i>F. Di Gennaro¹, D. Pizzol², K.d. Chhaganlal³, L. Monno¹, G. Putoto⁴, A. Saracino¹</i>
26	P 181	Perinatally HIV-infected youths after transition from paediatric to adult care, a single-centre experience from Northern Italy <i>I. Izzo¹, E. Quiros-rolan¹, B. Sacconi¹, E. Chiari¹, S. Casari¹, E. Focà¹, M.c. Pezzoli¹, M.a. Forleo¹, A. Bonito¹, R. Badolato², L. Dotta², F. Castelli¹</i>
47	P 182	HIV and pregnancy. Outcome of newborns exposed to antiretroviral therapy during gestational age: analysis of 80 cases <i>L. Trotta¹, L. Galli², G. Sterrantino³, M.trotta³</i>
Pharmacoeconomic issues		
176	P 183	Strategies for reducing Antiretroviral Therapy costs in Tuscany: the indications from the Regional Working Group and the integrated approach at Santa Maria Annunziata Hospital, Florence Area <i>F.m. Fusco¹, L. Rabatti², A. De Luca³, M.c. Burla², C. Braccini⁴, B. Del Pin¹, F. Baragli¹, T. Corona⁵, F. Vichi¹, P. Blanc¹</i>
362	P 184	Adherence to treatment, viral and immunologic response and healthcare resources use in HIV patients treated with single tablet ECFTDF versus multi-tablet (PI or INI) regimens <i>V. Perrone¹, D. Sangiorgi¹, L. Aledda¹, A. Chirianni², G. Di Perri³, N. Gianotti⁴, T. Quirino⁵, L. Degli Esposti¹</i>
89	P 185	Cost-effectiveness of ECFTAF in the Italian context <i>L. Pradelli¹, G. Di Perri², G. Rizzardini³, M. Povero¹</i>
94	P 186	The medical cost of the Hepatitis C Virus: the difference between HCV mono-infected and HIV/HCV co-infected patients <i>D. Croce^{1,2}, L. Ferrario¹, E. Foglia¹, E. Garagiola¹ On Behalf Of The Da Vinhci Study</i>
Pharmacology, pharmacogenomics and drug interactions		
144	P 187	Vitamin D pathway gene polymorphisms and GS-331007 sofosbuvir metabolite plasma concentrations are able to predict hepatocellular carcinoma in patients treated with direct acting antivirals <i>J. Cusato, L. Boglione, A. De Nicolò, F. Favata, F. Guido, S. Mornese Pinna, C. Carcieri, G. Cariti, G. Di Perri, A. D'avolio</i>
181	P 188	Deficiency of vitamin D increases efavirenz plasma exposure in HIV-positive patients <i>M. Tempestilli¹, J. Cusato², A.vergori¹, A. Ammassari¹, A. Antinori¹, A. D'avolio², C. Agrati¹</i>
24	P 189	Dolutegravir 50 mg thrice weekly plus unboosted Atazanavir daily in five long-term virologically suppressed HIV-infected patients <i>M. Lanzafame^{1,2}, E. Lattuada¹, S. Nicolè¹, F. Rigo¹, G. Cucchetto¹, E. Concia¹, S. Vento³</i>
62	P 190	Lactose intolerance doesn't influence plasmatic concentration of lactose-containing drugs and their efficacy: the case of an HIV-HCV coinfecting patient <i>C. Pallotto¹, L. Malincarne¹, F. Favata², F. Di Candilo¹, A. De Nicolò², F. Baldelli¹</i>
180	P 191	Antiretroviral plasma drug concentrations before and during DAA in a large, real-world-treated HIV/HCV co-infected population <i>M. Tempestilli, G. Fabbri, I. Mastroiosa, L. Timelli, S. Notari, R. Bellagamba, R. Libertone, F. Lupi, M. Zaccarelli, A. Antinori, C. Agrati, A. Ammassari</i>
85	P 192	Association of vitamin D gene polymorphisms with serological and virological response to interferon alpha in patients with active HBV infection and E genotype <i>J. Cusato¹, L. Boglione¹, A. De Nicolò¹, R. Imbornone¹, S. Mornese Pinna¹, C.s. Cardellino¹, V. Ghisetti², G. Cariti¹, G. Di Perri¹, A. D'avolio¹</i>
285	P 193	Evaluation of the switch to a dual ART regimen with lamivudine plus dolutegravir or protease inhibitors in HIV-infected virologically suppressed patients. A real life experience <i>M. Maritati¹, A. Trentini², S. Lo Menzo¹, D. Segala³, C. Contini¹, L. Sighinolfi³</i>
295	P 194	Intracellular simeprevir concentrations are increased by the co-administration of darunavir/ritonavir (first clinical report from the Kinetic C study) <i>A. Ariaudo, F. Favata, A. De Nicolò, L. Marinaro, C. Carcieri, E. Gontero, J. Cusato, S. Bonora, G. Di Perri, A. D'avolio</i>
301	P 195	Intracellular penetration of dolutegravir (DTG) and unboosted atazanavir (ATV) administered as dual regimen in the clinical setting <i>M. Ferrara, L. Marinaro, A. Ariaudo, C. Alcantarini, A. Barco, C. Montrucchio, A. De Nicolò, M. Tettoni, M. Milesi, C. Costa, A. Calcagno, G. Di Perri, A. D'avolio, S. Bonora</i>



Elenco Poster

ID	N. pgm	Title
98	P 196	A long-term retrospective observational study about switch strategies of antiretrovirals therapies in virologically suppressed patients: early results from the SO-CLOSE Study <i>D. Mengato¹, S. Cavinato², F. Brera³, G. Marini², N. Realdon¹, A.m. Cattelan²</i>
162	P 197	Association between sofosbuvir trough plasma concentrations and virological failure in anti-HCV treatment <i>A. De Nicolò, L. Boglione, C. Carcieri, J. Cusato, S. Mornese Pinna, F. Favata, A. Ariaudo, G. Di Perri, A. D'avolio</i>
128	P 198	Interactions between antiretroviral drugs and human Arginase 1 <i>L. Lisi¹, M. Pizzoferrato¹, G.m.p. Ciotti¹, F.t. Miscioscia², A. Topai², P. Navarra¹</i>
200	P 199	Cerebrospinal fluid abacavir penetration: once versus twice-daily administration <i>A. Calcagno¹, C. Pinnetti², A. Ariaudo¹, E. Scarvaglieri¹, M. Tempestilli², A. D'avolio¹, V. Fedele³, G. Di Perri¹, A. Antinori², S. Bonora¹</i>
302	P 200	The problem of interference between drugs and risk ADR in patients co-infected HIV/HCV in treatment with new antiviral action direct (DAAs) <i>G. Pensalfine, E. Meta, L. Appolloni, G. Piazza, M. Morotti, C. Puggioli</i>
357	P 201	Inadequate daclatasvir blood levels in a liver transplantation recipient treated with Sofosbuvir and Daclatasvir in association with ursodeoxycholic acid: a case report <i>L. Bussini¹, V. Guardigni^{1,2}, L. Badia^{1,2}, E. Francalanci¹, M. Rinaldi¹, M. Conti³, P. Viale^{1,2}, G. Verucchi^{1,2}</i>
399	P 202	Daclatasvir dosed at 60 mg/day in a patient taking Elvitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate: case report <i>E. Rosselli Del Turco¹, L. Badia^{1,2}, S. Coladonato¹, V. Guardigni^{1,2}, E. Francalanci¹, L. Bussini¹, P. Viale¹, G. Verucchi^{1,2}</i>

Programmatic issues, implementation of diagnosis and care

125	P 203	FLEW : Free to live well with HIV in prison <i>G. Starnini¹, S. Dell'isola², S. Babudieri³, A. Battistella⁴, M. Errico⁵, C. Frontini², F. Perocco⁴, Flew Group*</i>
169	P 204	A retention in care program in HIV patients: surprising results <i>M. Digaetano¹, A. Raimondi¹, A. Bonazza¹, A. Bianchi¹, A. Santoro¹, M. Menozzi¹, M. Rivasi², V. Borghi¹, G. Guaraldi¹, C. Mussini¹</i>
161	P 205	Adherence to lipid-lowering medication in HIV infected people in Modena HIV Outpatients Clinic: a Drug Direct Distribution experience <i>A. Raimondi¹, N. Riva¹, A. Bonazza¹, A. Santoro¹, M. Digaetano¹, I. Franconi¹, A. Bianchi¹, M. Rivasi², G. Guaraldi¹, C. Mussini¹, V. Borghi¹</i>
63	P 206	Retention in care of Italian HIV-positive patients at the Infectious Diseases Clinic of Perugia from 2005 to 2014 <i>C. Gabrielli, G.g. Mina, G. Angeli, C. Pallotto, E. Schiaroli, M.b. Pasticci, D. Francisci, F. Baldelli</i>
370	P 207	Measuring competent and reactivated HIV reservoir using TILDA <i>A. Bertoldi¹, M. Stoszko², I. Bon¹, G. Musumeci¹, S. Longo¹, V. D'urbano¹, C. Fazio¹, T. Mahmoudi², M.c. Re¹, E. De Crignis²</i>
230	P 208	Need for a better definition of "physical activity" among HIV infected population <i>E.n. Cavallari¹, I. Schietroma¹, G. Corano Scheri¹, C. Pinacchio¹, P. Vassalini¹, A. Salvati², P.e. Adami², M. Bernardi², G. Ceccarelli³, V. Vullo¹, G. D'ettore¹</i>
415	P 209	Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessment <i>M. Borderi¹, G. Angarano², A. Antinori³, A. Chirianni⁴, P. Cinque⁵, A. D'arminio Monforte⁶, A. Di Biagio⁷, G. Di Perri⁸, M. Galli⁹, A. Gori¹⁰, A. Lazzarin⁵, C. Mussini¹¹, C.f. Perno¹², T. Quirino¹³, G. Rizzardini¹⁴, B. Acone¹⁵, M. Andreoni¹⁶</i>
323	P 210	Ligurian Vaccination in HIV Program (LIV in HIV): the experience of Genoa metropolitan area <i>L. Sticchi^{1,5}, I. Barberis^{1,f}, Grammatico¹, V. Tisa¹, A. Di Biagio², G. Cenderello³, M. Giacomini⁴, B. Giannini⁴, F. Iavarone¹, V. Faccio¹, L.a. Nicolini^{1,2}, N. Riccardi², L. Taramasso², B. Bruzzone⁵, G. Mazzarello², G. Cassola³, C. Viscoli^{1,2}, G. Icardi^{1,5}</i>

Social and behavioural science, community aspects and community surveys

327	P 211	Comics against Stigma <i>L. Modesti, R. D'emidio</i>
131	P 212	Management of medications in people living with HIV <i>A. Battistella¹, D. Cattaneo², M. Errico³, R. Iardino⁴</i>
22	P 213	Italian "long-term survivors" <i>M. Zetti, A. Bianchi, M. Cernuschi</i>
93	P 214	HIV patients perceived quality of life: an analysis of QoL predictors <i>E. Foglia¹, E. Garagiola¹, L. Ferrario¹, D. Croce^{1,2}, F. Maggiolo³, T. Quirino⁴, P. Bonfanti⁵, G. Rizzardini^{6,7}, P. Meraviglia⁶, C. Atzori⁶</i>



Elenco Poster

ID	N. pgm	Title
7	P 215	Community Knowledge and Perception on MSM in BUEA the South West Region of Cameroon <i>P. Nguafac Temate Fongeh, C. Noutchie Nzesseu, G.i.l. Azegue</i>
172	P 216	So easy? A project towards the information about sexual transmitted diseases and administration of rapid HIV oral test". The crucial role of the Family Doctors <i>B. Bartocci, A.g. De Giorgio, S. Galeazzi, S. Guerrucci, C. Minelli, M. Nardi, B. Pilati, R. Tenca</i>
352	P 217	Does HIV concern us? A preliminary study about HIV/AIDS risk perceptions and health Locus of Control in Italian general population <i>M.m. Ratti, F. Bertin, E. Soldi, V. Salverani, S. Ardenghi, M.g. Strepparava</i>
9	P 218	Found your poetry <i>A. Infante</i>
75	P 219	The Socio-affective Network and Self-Efficacy in adherence to antiretroviral therapy <i>S. Giglio, V. Fortunato, A. Masiello, S. Leone, M. Talamo, N. Acone</i>
167	P 220	Aids Free Generation. Awareness-raising campaign to overcome stereotypes and promote a culture of safe and conscious sexuality. The project <i>B. Bartocci, A.g. De Giorgio, S. Galeazzi, S. Guerrucci, M. Nardi, B. Pilati, R. Tenca</i>
168	P 221	Aids Free Generation. The awareness-raising campaign <i>B. Bartocci, A.g. De Giorgio, S. Galeazzi, S. Guerrucci, M. Nardi, B. Pilati, R. Tenca</i>
171	P 222	So easy? A project towards the information about sexual transmitted diseases and administration of rapid HIV oral test <i>B. Bartocci, A.g. De Giorgio, S. Galeazzi, S. Guerrucci, C. Minelli, M. Nardi, B. Pilati, R. Tenca</i>
205	P 223	Low prevalence of HTLV1/2 infection in a population of sub-Saharan immigrants living in Southern Italy <i>L. Alessio^{1,2,3}, L. Occhiello¹, M. Caroprese², E. Sagnelli¹, C. Sagnelli^{1,2,4}, L. Gualdieri⁵, M. Pisaturo^{2,3,4}, C. Minichini¹, G. Di Caprio², M. Starace¹, L. Onorato^{1,2}, G. Scotto⁶, M. Macera^{1,2}, S. De Pascalis¹, N. Coppola¹</i>
1	P 224	Using Peer Educators Recruited from Populations at High Risk for HIV Acquisition to Improve HIV Testing and Counseling Uptake KUMBA Cameroon <i>A. Fontu, N.g. Tanyi, Y.s. Chupiwoh</i>
298	P 225	A multidisciplinary approach by physician and clinical pharmacist to increase adherence to HAART in a cohort of HIV infected patients <i>E. Meta, G. Pensalfine, L. Appolloni, G. Piazza, M. Morotti, C. Puggioli</i>
353	P 226	Home-based care for HIV/AIDS patients: the experience of a North Italy Centre in the post HAART era <i>M. Fiscon¹, S. Magrin¹, P. Di Ruscio¹, D. Signorelli², M. Malena¹</i>
164	P 227	The experience of Unità di Strada "Cabiria" with Rapid HIV Oral Test <i>B. Bartocci, A.g. De Giorgio, S. Galeazzi, S. Guerrucci, M. Nardi, B. Pilati, R. Tenca</i>
129	P 228	The Case of Test Days in Modena: How can Psychology of Prevention Enhance HIV Counselling and Testing Impact <i>A. Toscano¹, A. Bignardi², A. Santoro³, M. De Paola², C. Mussini³</i>
372	P 229	From curing to caring. What do Italians know about HIV/AIDS? <i>G. Bonadies, F. Corbisiero, M. Errico, S. Monaco, G. Ranisio</i>
Virology		
408	P 230	Description of clinical and molecular characteristics of a group of chronic hepatitis C infected patients who had undergone a DAA re-treatments: our region experience <i>E. Rappazzo^{1,2}, P. Canepa^{1,2}, L. Nicolini³, S. Marengo⁴, B. D'ambrosio^{1,2}, C. Arcuri^{1,2}, C. Dentone⁵, V. Bartolacci⁶, L. Bruzzone⁷, G. De Rosa², L. Sticchi^{1,2}, A. Picciotto⁴, C. Viscoli³, A. Grasso⁷, G. Icardi^{1,2}, B. Bruzzone²</i>
126	P 231	Virological patterns of HCV-patients with failure to Interferon-free regimens <i>M. Starace¹, C. Minichini¹, S. De Pascalis¹, M. Macera¹, L. Occhiello¹, V. Messina², V. Sangiovanni³, L.e. Adinolfi⁴, E. Claar⁵, D.f. Precone⁶, G. Stornaiuolo¹, T. Ascione⁷, R. Zampino⁸, G. Parrilli⁹, M. Stanzione¹, A. Federico¹⁰, I. Gentile¹¹, V. Iovinella¹², S. Martini¹³, M. Masarone¹⁴, L. Fontanella¹⁵, A. Masiello¹⁶, R. Punzi¹⁷, A. Salomone Megna¹⁸, R. Santoro¹⁹, G.b. Gaeta¹, N. Coppola¹</i>
174	P 232	Prevalence of integrase strand transfer inhibitors (INSTI) resistance mutations in INSTI-naive and INSTI-experienced HIV-1 infected patients: a single-Centre experience <i>M.a. De Francesco¹, M. Properzi², F. Gargiulo¹, I. Izzo², F. Caccuri¹, F. Castelli², A. Caruso¹, E. Focà²</i>
351	P 233	Impact of resistance mutations in the protease and reverse transcriptase on the replicative capacity of HIV-1 in recent and non-recent infections <i>S. Caucci¹, P. Bagnarelli¹, M. Franzetti², M. Andreoni³, C. Balotta², S. Menzo¹</i>



Elenco Poster

ID	N. pgm	Title
406	P 234	HBsAg mutations in hematological patients with HBV reactivation <i>P. Caligiuri^{1,2}, M. Mikulska³, L. Nicolini³, G. Barisone^{1,2}, G. Guarona^{1,2}, R. Cerruti², G. Icardi^{1,2}, B. Bruzzone²</i>
314	P 235	Measurements of total, unintegrated and integrated cell-associated HIV-1 DNA in elite controllers, long-term nonprogressor, on ART progressors and treatment-naïve patients <i>C. Orlandi¹, F. Marras^{2,3}, F. Bozzano^{2,4}, B. Canovari⁵, M.I. Ascierio⁶, A. Di Biagio⁷, E. Pontali⁸, C. Dentone⁹, G. Orofino¹⁰, L. Nicolini^{7,11}, L. Taramasso¹¹, F. Marincola¹², E. Wang¹², L. Moretta¹³, F. Barchiesi⁵, A. De Maria^{2,7,11}, M. Magnani¹, A. Casabianca¹</i>
154	P 236	HTLV-I associated ATL: application of a SYBR GREEN real time PCR to evaluate size proviral reservoirs after chemotherapy and antiretroviral treatment <i>G. Musumeci¹, I. Bon¹, S. Longo¹, A. Bertoldi¹, V. D'urbano¹, L. Marconi², L. Calza², M.c. Re¹</i>
215	P 237	Effects of Amprenavir on HIV-1 Maturation, Production and Infectivity following drug withdrawal in Chronically Infected Monocytes/Macrophages <i>A. Borrajo^{1,3}, V. Svicher¹, C. Alteri¹, C.f. Perno¹, S. Aquaro^{1,2}</i>
407	P 238	Prevalence of NS3, NS5A and NS5B resistance associated variants in patients experienced a virological failure <i>P. Canepa^{1,2}, E. Rappazzo^{1,2}, S. Marengo³, L. Nicolini⁴, S. Delucis^{1,2}, C. Arcuri^{1,2}, M. Lo Casto², G. Cenderello⁵, C. Dentone⁶, I. De Macina⁶, V. Bartolacci⁷, P. De Leo⁸, F. Malfatti⁹, E. Giannini³, M. Setti¹⁰, R. Prinapori¹¹, A. Di Biagio⁴, B. Bruzzone²</i>